NCT04286841View on ClinicalTrials.gov

The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2029

Conditions
ImmunotherapyLung Cancer
Interventions
DRUG

Immunotherapy

Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.

Trial Locations (1)

510080

RECRUITING

Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou

All Listed Sponsors
lead

Guangdong Association of Clinical Trials

OTHER